Browse the evidence

Continuous Positive Airway Pressure (CPAP) therapy effectively improves daytime sleepiness and quality of life in Obstructive Sleep Apnoea (OSA) patients, but its impact on cardiometabolic outcomes is uncertain and secondary prevention trials have failed to demonstrate significant modification of cardiovascular events.

CPAP is the most effective treatment for stopping snoring and fixing daytime sleepiness in OSA patients. However, do not expect it to automatically fix your heart health or blood sugar levels, as evidence for those benefits is weak. If you struggle with the mask, talk to your doctor about alternatives like oral appliances or nerve stimulation, as adherence is a major hurdle.

Physical activity and exercise provide significant health benefits for adults with overweight or obesity independent of weight loss, including improvements in body composition quality, cardiorespiratory fitness, and metabolic health.

Prioritize regular physical activity regardless of your current weight. Focus on building cardiorespiratory fitness and muscle strength, as these provide health benefits even if you do not lose weight. Do not let the absence of scale movement discourage you from exercising.

GLP-1 receptor agonists and incretin co-agonists reduce total body weight primarily through adipose tissue loss, but this process involves an absolute reduction in lean mass (skeletal muscle) that typically accounts for 20–30% of the total weight lost.

If you are taking GLP-1 medications, expect to lose some muscle along with fat. To minimize this, prioritize resistance training and adequate protein intake. This helps preserve strength and metabolic health despite the inevitable lean mass reduction.

Tirzepatide significantly reduces the apnea-hypopnea index (AHI) and body weight in patients with moderate to severe obstructive sleep apnea (OSA) and obesity, regardless of whether they are using positive airway pressure (PAP) therapy.

If you have moderate to severe sleep apnea and obesity, Tirzepatide is a newly FDA-approved treatment that significantly reduces breathing interruptions during sleep and leads to substantial weight loss (18-20%). It works not just by shrinking fat around the airway, but also by reducing inflammation and affecting brain signals related to sleep. You can use it alone or alongside your CPAP machine. Because rapid weight loss can affect muscle, you should combine this medication with strength training and nutritional counseling.

GLP-1 receptor agonists (specifically Liraglutide) improve OSA outcomes when used in combination with CPAP, but CPAP alone is superior to Liraglutide monotherapy for reducing cardiovascular inflammation and plaque volume.

If you have severe sleep apnea and diabetes, adding Liraglutide to your CPAP therapy can further reduce breathing interruptions compared to using Liraglutide alone. However, CPAP is still necessary for protecting your heart and reducing arterial plaque, as Liraglutide alone does not provide this specific cardiovascular benefit. If you struggle with CPAP, discuss combination strategies with your doctor.

Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.

If you have metabolic risk factors like obesity or type 2 diabetes, ask your doctor for a FIB-4 score. It is a simple, low-cost calculation using age, AST, ALT, and platelet count that helps identify liver fibrosis risk early.

Endoscopic bariatric therapies (EBMTs), including intragastric balloons and endoscopic sleeve gastroplasty, provide significant weight loss and metabolic improvements as minimally invasive alternatives to surgery, though they are associated with specific adverse events and potential weight regain.

Endoscopic bariatric therapies are a viable, minimally invasive option for weight loss, particularly for those who cannot or will not undergo surgery. Procedures like intragastric balloons and endoscopic sleeve gastroplasty can achieve significant weight loss (25-60% excess weight loss) when combined with lifestyle changes. However, they are not risk-free, with potential side effects ranging from nausea to rare serious complications. Patients should discuss their BMI, health status, and preference for invasiveness with a specialist to determine if an EBMT is appropriate, keeping in mind that some devices are temporary and may require combination with medication or surgery for long-term success.

GLP-1 receptor agonist therapy induces lean mass loss proportional to fat loss (approx. 25% of total weight loss), which is a physiological response to caloric restriction rather than a unique pathological catabolic effect of the drug.

If you are taking a GLP-1 drug like Semaglutide, expect to lose about 25% of your total weight as muscle. This is normal and similar to losing weight through diet alone. To protect your muscle, prioritize resistance training and eat 1.2-1.6g of protein per kg of body weight daily.

Semaglutide induces body weight loss and metabolic remodeling beyond caloric restriction alone, driven by intake-independent mechanisms including adipose tissue browning, increased sympathetic innervation, and sustained locomotor activity.

Semaglutide provides metabolic benefits that go beyond simply eating less. It promotes fat loss through biological changes like increasing brown fat activity and reducing fat cell size, independent of how much you eat. This suggests that patients may achieve better results with semaglutide than with dieting alone, even if their food intake is similar.

In oncology patients, muscle-specific strength (MSS) estimated via anthropometry (body weight or calf circumference) or bioimpedance (BIA) provides a reliable alternative to DXA-derived MSS, enabling functional assessment in resource-limited settings.

For cancer patients or clinicians without access to DXA scanners, you can accurately estimate muscle quality by dividing handgrip strength by body weight or calf circumference. This method correlates very strongly with the gold standard DXA test, allowing for effective monitoring of sarcopenia and treatment response in routine clinical settings.

Lean MASLD (normal BMI but with metabolic dysfunction) is a distinct phenotype driven by sarcopenia, adverse fat distribution, and genetic susceptibility, requiring different treatment strategies than obesity-driven MASLD.

If you have a normal BMI but metabolic issues (like high blood sugar or blood pressure), you can still develop fatty liver disease. This 'lean MASLD' is often linked to low muscle mass and genetics. Focus on building muscle and managing metabolic health rather than just losing weight.

Dietary weight loss stabilizes the proportion of lean mass lost (%LML) at approximately 25-33% once total weight loss exceeds 5%, contradicting the hypothesis that lean loss increases proportionally with greater weight loss.

When you lose weight through diet, you will lose some muscle along with fat. This is normal and accounts for about 25-33% of the total weight lost, regardless of how much weight you lose. Men tend to lose a slightly higher percentage of lean mass than women. To minimize this, combine your diet with resistance training and adequate protein intake, but do not fear that larger weight loss equals disproportionately larger muscle loss.

Diet-based weight loss interventions result in minimal loss of appendicular lean soft tissue (a surrogate for skeletal muscle), with losses accounting for less than 10% of total mass loss after adjusting for fat-free adipose tissue.

If you are losing weight through diet alone (without resistance training), you will not lose significant muscle mass. The study found that lean tissue loss was minimal (less than 10% of total weight lost) and that your muscle mass relative to your new body size actually increased. You do not need to fear muscle loss as a barrier to starting a diet.

Nutritional interventions (protein, leucine, HMB, creatine) preserve or modestly increase lean mass in sarcopenia but fail to consistently restore muscle strength or physical function when applied in isolation.

Eat enough protein (at least 1.2g per kg of body weight daily) and consider creatine or HMB, but do not expect these supplements to fix your strength or balance on their own. You must combine them with resistance exercise to see functional benefits. Nutrition primes the muscle, but exercise builds the function.

Consumption of fermented foods is associated with improved gut microbiome diversity, reduced inflammation, and metabolic health benefits, regardless of whether the product contains live microbes or is pasteurized.

Incorporate a variety of fermented foods (yogurt, kefir, sauerkraut, kimchi) into your diet. You do not need to worry if they are pasteurized; both live and dead microbes (postbiotics) offer benefits. If you have high blood pressure, choose lower-sodium options like yogurt or kefir over salty pickles, and consult your doctor if you are immunocompromised or have histamine intolerance.

For middle-aged and elderly adults with type 2 diabetes, maintaining a longitudinal BMI within 18.5–26.9 kg/m² significantly reduces all-cause, cardiovascular, and cancer mortality compared to lower or higher sustained BMI levels.

If you have type 2 diabetes, aim to keep your BMI between 18.5 and 26.9 kg/m² over the long term. This range is associated with the lowest risk of death from all causes, heart disease, and cancer. Avoid sustained periods where your BMI is consistently above 27 kg/m², as this increases mortality risk.

Sustained exposure to a BMI of 27 kg/m² or higher is positively associated with increased all-cause, cardiovascular, and cancer mortality in patients with type 2 diabetes.

Keep your BMI below 27 kg/m². Sustained exposure to a BMI of 27 or higher increases your risk of dying from heart disease, cancer, or other causes. If your BMI is consistently above 27, work with your doctor to lower it gradually.

Higher plasma levels of the gut microbiome-derived metabolite Trimethylamine-N-oxide (TMAO) are associated with a significantly higher risk of incident atherosclerotic cardiovascular disease (ASCVD) in a diverse, community-based population free of prior cardiovascular disease.

This study suggests that higher levels of TMAO, a byproduct of gut bacteria processing nutrients like red meat and eggs, are linked to a higher risk of heart disease. While it doesn't tell you to eliminate these foods, it highlights the importance of your gut health and kidney function. If you have risk factors for heart disease, discussing your diet and TMAO levels with your doctor might be worthwhile, especially if you have reduced kidney function.

Acute exercise (both HIIT and MICT) results in more phosphosite down-regulation than up-regulation, suggesting that acute exercise involves the inhibition of kinase activity and/or activation of phosphatases.

Exercise doesn't just turn things on; it also turns things off. This balance is crucial for adaptation. Don't assume more activation is always better; regulation (inhibition) is part of the process.

Tirzepatide has surpassed semaglutide as the most commonly prescribed first-time GLP-1 RA medication in the US as of September 2025.

Tirzepatide is now the most frequently prescribed first-time GLP-1 medication in the US, overtaking semaglutide. This reflects changing prescribing preferences among physicians.

Lean individuals with Metabolic Dysfunction-Associated Fatty Liver Disease (lean-MAFLD) face a significantly higher risk of liver-related mortality compared to overweight or obese MAFLD patients, despite having equivalent metabolic profiles and similar risks for extrahepatic mortality.

If you are lean but have been diagnosed with fatty liver (MAFLD), do not assume you are safe because you are thin. Your risk of liver-related death is actually higher than that of obese patients with the same condition. Standard weight loss advice, especially rapid loss via drugs, can be dangerous for you because it strips away muscle, which your liver needs. Focus on metabolic health markers (blood pressure, glucose, lipids) and consult your doctor about treatments that preserve muscle mass rather than just focusing on weight loss.

None of the tested dietary supplements (protein, creatine, HMB) significantly increased lean body mass in athletes when combined with strength and conditioning training.

Do not expect supplements like protein, creatine, or HMB to significantly increase your muscle mass on their own. Focus on your training and overall diet. This analysis found no significant benefit for muscle mass from these supplements in trained athletes.

Sleeve gastrectomy is associated with a higher risk of new-onset or worsening gastroesophageal reflux disease (GERD) compared to Roux-en-Y gastric bypass (RYGB).

If you have existing or severe acid reflux, Roux-en-Y gastric bypass is likely a safer choice than sleeve gastrectomy, as the sleeve procedure carries a higher risk of causing or worsening reflux.

Metabolic/bariatric surgery (MBS) is the most cost-effective intervention for class II and III obesity, often demonstrating dominance (cost-saving) over non-surgical management.

For individuals with Class II or III obesity, metabolic/bariatric surgery is the most economically and clinically effective long-term solution, often paying for itself through reduced healthcare costs from comorbidity remission. It should be prioritized over pharmacotherapy for this group.